Breast cancer and normal cell lines
|
|
|
- Evelyn Patrick
- 7 years ago
- Views:
Transcription
1 The Essentials of Life Science Research Globally Delivered Breast cancer and normal cell lines ATCC No. Name Tissue Cell Type Disease Oganism Age Ethnicity Genes Expressed CRL-7227 Hs 281.T CRL-7245 Hs 343.T CRL-7253 Hs 362.T HTB-132 HTB-27 CRL-2351 HTB-22 HTB-26 HTB-128 HTB-130 HTB-21 HTB-30 MDA-MB-468 MDA-MB-361 AU565 [AU-565] MCF7 MDA-MB-231 MDA-MB-415 MDA-MB-436 CAMA-1 SK-BR-3 : brain : malignant pleural : pleural : pleural : pleural : pleural : pleural : pleural 37 years 47 years 78 years 51 years Black 40 years wnt7h + 43 years 69 years 51 years 38 years, 43 years tubulin; actin Blood Type AB; HLA Aw23, Aw30, B27, Bw35, Cw2, Cw4 (patient) her2/neu + (overexpressed); her3 +; her4 +; p53 + insulin-like growth factor binding proteins (IGFBP) BP-2; BP-4; BP-5, Blood Type O; Rh+ amelogenin (X chromosome)(amelex), Blood Type O 51 years Blood type O; Rh +; HLA A10, A11, B12, B18 43 years Blood Type A; Rh+; HLA A11, Bw22(+/-), B40, B18
![T HTB-132 HTB-27 CRL-2351 HTB-22 HTB-26 HTB-128 HTB-130 HTB-21 HTB-30 MDA-MB-468 MDA-MB-361 AU565 [AU-565] MCF7 MDA-MB-231 MDA-MB-415 MDA-MB-436 CAMA-1 SK-BR-3 : brain : malignant pleural : pleural :](/docs-images/47/20779604/images/page_1.jpg "pleural : pleural : pleural : pleural : pleural 37 years 47 years 78 years 51 years Black 40 years wnt7h + 43 years 69 years 51 years 38 years, 43 years tubulin; actin Blood Type AB; HLA Aw23, Aw30,")
2 CRM-HTB-26 MDA-MB-231 : pleural CRL-2116 JC mammary gland, -like CRL MAT B III mammary gland CRL-1743 NMU mammary gland CRL-1747 RBA mammary gland CRL-3127 CRL-3180 CRM-HTB- 26D UACC-1179 UACC-2087 MDA-MB-231 CRL-7222 Hs 274.T CRL-7477 Hs 739.T CRL-7480 Hs 741.T ; derived from metastatic site: pleural fluid : pleural -like CRL-6602 SMT/2A LNM mammary gland CRL-7486 Hs 748.T HTB-125 HTB-126 HTB-19 CRL-7347 CRL-1897 HTB-121 HTB-122 Hs 578Bst Hs 578T BT-20 Hs 579.Mg UACC-812 BT-483 BT-549 CRL-7345 Hs 574.T HTB-20 BT-474 /duct /duct, Myo fibroblast cancer Carcinoma Carcinoma Carcinoma ductal ductal ductal ductal ductal 51 years 1.5 years 50 days 50 days 61 years 51 years 51 years 66 years 52 years Asian 47 years 48 years 74 years 74 years collagen (Type IV); plasminogen activator; prostaglandins; keratin keratin 74 years HLA A1, Bw16 (+/-) 43 years 23 years 72 years 60 years 2 Order online at call , , or contact your local distributor.
3 CRL-1500 CRL-2865 HTB-133 HTB-23 HTB-25 CRL-1504 ZR-75-1 T47D-KBluc T-47D MDA-MB-134-VI MDA-MB-175-VII ZR /duct: ascites /duct: pleural /duct: pleural /duct: pleural /duct: pleural : ascites transfected with reporter plasmid ductal ductal ductal ductal ductal ductal CRL-3121 UACC-2648 /duct -like ductal CRL CRL CRL CRL-7329 CRL-2983 MCF 10A MCF 10F MCF-10-2A Hs 564(E).Mg UACC-3199 CRL-7236 Hs 319.T CRL-2988 CRL-3166 UACC-3133 UACC-732 / duct: axillary lymph node : pleural ; derived from metastatic site: pleural fluid, Myo -like fibrocystic disease fibrocystic disease fibrocystic disease infiltrating ductal infiltrating ductal of the infiltrating ductal cell infiltrating lobular of inflammatory of the CRL-2755 EMT6 mammary HTB-24 HTB-131 MDA-MB-157 MDA-MB-453 /medulla : pericardial medulallary metastatic 63 years 54 years 54 years 47 years 56 years Black 47 years Black 58 yrs 36 years 36 years 36 years 53 years 58 years 42 years 52 years 33 years 44 years Black 48 years mucin (apomucin, MUC-1, MUC-2) Blood Type O; Rh+ cytokeratin 19. The cells are positive for cytokeratins and milk fat globule antigen. c-erbb-2 positive Blood Type B; Rh- Order online at call , , or contact your local distributor. 3
4 CRL-8400 CSMalphabeta6C [CSMab6C] mammary gland fibroblast Papilloma CRL-8399 CMH1a mammary gland Papilloma, hepatitis, hepatitis CRL-8401 CRL-1902 CMalphabeta1h [CMab1h] UACC-893 CRL-7482 Hs 742.T mammary gland fibroblast Papilloma, Papilloma, Papilloma CRL T1 mammary gland CRL-2324 CRL-2338 CRL-2320 CRL-2321 CRL-2322 CRL-2335 CRL-2329 HCC1395 HCC1954 HCC1008 HCC1143 HCC1187 HCC1806 HCC1500 /duct /duct /duct: lymph node /duct /duct /duct, lymphoblast primary ductal scirrhous This tumor is an animal stage IV human cancer. TNM stage I, grade 3, primary ductal TNM stage IIA, grade 3, ductal TNM stage IIA, grade 3, ductal TNM stage IIA, grade 3, primary ductal TNM stage IIA, grade 3, primary ductal TNM stage IIB, grade 2, primary acantholytic squamous cell TNM stage IIB, grade 2, primary ductal 57 years 71 years 43 years 61 years 67 years 52 years 41 years, East Indian Black, 60 years Black 32 years Black glycoprotein hormones, alpha polypeptide(chorionic gonadotropin, alpha polypeptide, luteinizing hormone alpha) [CGA], chorionic gonadotropin, beta polypeptide, glycoprotein hormones, alpha polypeptide surface antigen [sag] glycoprotein hormones, alpha polypeptide(chorionic gonadotropin, alpha polypeptide, luteinizing hormone alpha) [CGA], chorionic gonadotropin, beta polypeptide, glycoprotein hormones, alpha polypeptide glycoprotein 2 (EGP2), cytokeratin 19, her2/neu -, p53 +, The cells are negative for expression of Her2-neu but positive for expression of p53., The cells are negative for expression of estrogen receptors (ER -) according to depositor and negative for expression of progesterone receptors (PR -). HCC1954 overexpresses her2/neu and is positive for the cell specific marker Glycoprotein 2 and for cytokeratin 19, and is negative for expression of estrogen receptor (ER) and progesterone receptor (PR). glycoprotein 2 (EGP2), cytokeratin 19, her2/ neu +, p53 +, The cells are positive for expressions of Her2-neu and p53 oncogenes., The cells are negative for expression of estrogen receptor (ER) and for expression of progesterone receptor (PR). glycoprotein 2 [EGP2]; cytokeratin 19, her2/ neu -; p53 +, The cells are negative for expression of Her2-neu but positive for expression of p53., HCC1143 is positive for the cell specific marker Glycoprotein 2 and for cytokeratin 19, and is negative for expression of estrogen receptor (ER) and progesterone receptor (PR). glycoprotein 2 (EGP2), cytokeratin 19, her2/neu -, p53 + glycoprotein 2 [EGP2]; cytokeratin 19, her2/neu -, p53 -, The cells are negative for expression of Her2-neu and for expression of p53., The cells are negative for expression of estrogen receptor (ER) and for expression of progesterone receptor (PR). glycoprotein 2 (EGP2), cytokeratin 19, her2/ neu -, p53 +, The cells are negative for expression of Her2-neu but positive for expression of p53., The cells are positive for expression of estrogen receptor (ER) and for expression of progesterone receptor (PR). 4 Order online at call , , or contact your local distributor.
5 CRL-2314 CRL-2336 CRL-2340 CRL-2316 CRL-2331 CRL-2326 CRL-2343 CRL-2315 CRL-2330 HCC38 HCC1937 HCC2157 HCC202 HCC1599 HCC1419 HCC2218 HCC70 HCC1569 /duct /duct /duct /duct /duct /duct /duct lymphoblast,, lymphoblast, lymphoblast TNM stage IIB, grade 3, primary ductal TNM stage IIB, grade 3, primary ductal TNM stage IIIA, grade 2, primary ductal TNM stage IV, grade 3, primary metaplastic 50 years 23 years 48 years 82 years 44 years, Black,, 42 years Hispanic 38 years, 49 years Black 70 Black The cells are negative for expression of Her2-neu but positive for expression of p53, HCC38 is positive for the cell specific marker Glycoprotein 2 [EGP2] and for cytokeratin 19, and is negative for expression of estrogen receptor (ER) and progesterone receptor (PR). glycoprotein 2 (EGP2), cytokeratin 19, BRCA1 (mutated, insertion C at nucleotide 5382), her2/neu -, p53 -, The cells are negative for expression of Her2-neu and for expression of p53., The cells are negative for expression of estrogen receptor (ER) and progesterone receptor (PR) glycoprotein 2 [EGP2]; cytokeratin 19, her2/neu +, p53 +, The cells are positive for expression of Her2-neu and for expression of p53., The cells are negative for expression of estrogen receptor (ER -), but positive for expression of progesterone receptor (PR +). glycoprotein 2 [EGP2]; cytokeratin 19, her2/neu +, p53 -, The cells are positive for expression of Her2-neu, but are negative for expression of p53., The cells are negative for expression of estrogen receptor (ER -) and progesterone receptor (PR -). glycoprotein 2 [EGP2]; cytokeratin 19, her2/neu -, p53 -, The cells are negative for expression of Her2-neu and for expression of p53., The cells are negative for expression of estrogen receptor (ER) and for expression of progesterone receptor (PR). glycoprotein 2 [EGP2]; cytokeratin 19, her2/ neu +, p53 -, The cells overexpress Her2-neu but are negative for expression of p53. HCC1419 is positive for the cell specific marker glycoprotein 2 (EGP2) and for cytokeratin 19. The cells are negative for expression of estrogen receptor (ER) and for expression of progesterone receptor (PR). glycoprotein 2 [EGP2]; cytokeratin 19, her2/ neu +, p53 +, The cells are highly positive for expression of Her2/neu, and are also positive for expression of p53., The cells are negative for expression of estrogen receptor (ER -). glycoprotein 2 [EGP2]; cytokeratin 19, her2/neu -, p53 + (overexpressed), The cells overexpress p53, and are negative for the expression of Her2-neu oncogenes., The depositor of CRL-2315 initially reported the cells were positive for estrogen receptors. glycoprotein 2 [EGP2]; cytokeratin 19, her2/ neu +, p53 -, positive for expression of Her2-neu and negative for expression of p53., The cells are negative for expression of estrogen receptor (ER) and for expression of progesterone receptor (PR) by immunohistochemistry, but PR expression was detectable at a low level by cytosolic protein assay. Order online at call , , or contact your local distributor. 5
6 CRL-2327 HCC1428 mammary gland; : and pleural CRL-1616 C127I mammary gland CRL CRL CRL-2713 MCF-12A MCF-12F MDA-kb2 CRL-7365 Hs 605.T CRL-7940 HTB-123 CRL-8798 CRL-8799 SW527 [SW 527, SW-527] DU A1 184B5 CRL-7721 MB 157 /epithelium /epithelium /pleural : pleural CRL-6299 CMMT mammary gland CCL-51 MMT mammary gland CRL-1615 CL-S1 mammary gland CRL-1636 NMuMG mammary gland CRL-1804 C127: LT mammary gland CRL-6376 MM3MG mammary gland TNM stage IV, grade 4, visualization of sarcoma virus-induced foci and for an in vitro quantitative assay for bovine papilloma virus. Host for transfection with plasmids containing bovine papilloma virus DNA., visualization of sarcoma virusinduced foci and for an in vitro quantitative assay for bovine papilloma virus. Host for transfection with plasmids containing bovine papilloma virus DNA., transfection with plasmids containing bovine papilloma virus DNA., s for transformation with bovine papilloma virus DNA plasmid Macaca mulatta 49 years 60 years, 60 years 48 years 61 years HCC1428 cells are positive for the expression of glycoprotein 2 [EGP2]; cytokeratin 19 mucin, milk fat globule membrane antigen, sialomucin, The cells are positive for cytokeratins 8, 14 and 18, and negative for cytokeratin 19. Cells derived from a floating population are available (see MCF-12F, ATCC CRL-10783). luciferase, androgen receptor 70 years blood type A; Rh+ 70 years 21 years 21 years 48 years Black plasminogen activator (low amounts) 6 Order online at call , , or contact your local distributor.
7 CRL-6378 MM5MTC mammary gland CRL /+ MGT mammary gland CRL-2283 LA7 mammary gland CRL-6599 Rn2T mammary gland CRL-6230 CF37.Mg mammary gland CRL-6232 CF41.Mg mammary gland CRL-7336 Hs 566(B).T CRL-7368 Hs 606.T CRL-3063 Eph4Ev Mammary Epithelium CRL-3069 B-MEKDD 116 Mammary CRL-3071 Eph Mammary CRL-3086 M158 Mammary CRL-3090 NF639 Mammary CRL-3092 Ac 711 Mammary CRL-1637 Mm5MT mammary gland CRL-7242 Hs 329.T CRL-7256 Hs 371.T CRL-7145 Hs 190.T CRL-7246 Hs 344.T CRL-7248 Hs 350.T CRL-7379 Hs 617.Mg CRL-7574 Hs 841.T CRL-7583 Hs 849.T CRL-7584 Hs 851.T Canis familiaris Canis familiaris 2 years 2 years 10 years 35 years 44 years 54 years 28 years 11 years 49 years 55 years 71 years 48 years 41 years 61 years mouse mammary tumor virus (MMTV) and MMTV antigens Order online at call , , or contact your local distributor. 7
8 CRL-7596 Hs 861.T CRL-7612 Hs 875.T CRL-6373 MM2MT mammary gland CRL-6449 RIIIMT mammary gland CRL-6598 Rn1T mammary gland CRL-6231 CF38.Mg mammary gland CRL-6228 CF34.Mg spontaneous tumor Canis familiaris Canis familiaris 42 years 21 years 2 years 2 years 10 years PHONE tech@atcc.org WEB CB American Type Culture Collection. The ATCC trademark and trade name, any and all ATCC catalog numbers and any other trademarks listed in this publication are trademarks of the American Type Culture Collection unless indicated otherwise. These products are for laboratory use only. Not for human or diagnostic use. ATCC products may not be res, modified for resale, used to provide commercial services or to manufacture commercial products without prior ATCC written approval.
Colon cancer and normal cell lines
The Essentials of Life Science Research Globally Delivered Colon cancer and normal cell lines ATCC No. Name Tissue Cell Type Disease Oganism Age Ethnicity Genes Expressed CRL-2577 RKO Carcinoma CRL-2579
Breast Cancer Resource Book
TM Breast Cancer Resource Book Breast Cancer Resource BOOK Table of Contents Introduction 1 Tumor Cell Lines 2 Tumor Cell Panels 3 htert immortalized Cells 4 Primary Cells 5 Culture and Assay Reagents
Breast Cancer. The Pathology report gives an outline on direction of treatment. It tells multiple stories to help us understand the patient s cancer.
Breast Cancer What Does the Pathology Report Say Normal Cells The Pathology report gives an outline on direction of treatment. It tells multiple stories to help us understand the patient s cancer. Non-Invasive
Your Guide to the Breast Cancer Pathology Report
Your Guide to the Breast Cancer Pathology Report Developed for you by Breastcancer.org is a nonprofit organization dedicated to providing education and information on breast health and breast cancer. The
Breast Cancer. CSC Cancer Experience Registry Member, breast cancer
ESSENTIALS Breast Cancer Take things one step at a time. Try not to be overwhelmed by the tidal wave of technical information coming your way. Finally you know your body best; you have to be your own advocate.
Your Guide to the Breast Cancer Pathology Report
Your Guide to the Breast Cancer Pathology Report Developed for you by Breastcancer.org is a nonprofit organization dedicated to providing education and information on breast health and breast cancer. The
Changes in Breast Cancer Reports After Second Opinion. Dr. Vicente Marco Department of Pathology Hospital Quiron Barcelona. Spain
Changes in Breast Cancer Reports After Second Opinion Dr. Vicente Marco Department of Pathology Hospital Quiron Barcelona. Spain Second Opinion in Breast Pathology Usually requested when a patient is referred
Practical Effusion Cytology
Practical Effusion Cytology A Community Pathologist s Approach to Immunocytochemistry in Body Fluid Cytology Emily E. Volk, MD William Beaumont Hospital Troy, MI College of American Pathologists 2004.
Understanding your pathology report
Understanding your pathology report 2 Contents Contents Introduction 3 What is a pathology report? 3 Waiting for your results 4 What s in a pathology report? 4 Information about your breast cancer 5 What
Bone cancer and normal cell lines
The Essentials of Life Science Research Globally Delivered Bone cancer and normal cell lines ATCC No. Name Tissue Cell Type Disease Oganism Age Ethnicity Genes Expressed CRL-1873 RS4;11 marrow lymphoblast
Breast Cancer: from bedside and grossing room to diagnoses and beyond. Adriana Corben, M.D.
Breast Cancer: from bedside and grossing room to diagnoses and beyond Adriana Corben, M.D. About breast anatomy Breasts are special organs that develop in women during puberty when female hormones are
Breast Cancer. Sometimes cells keep dividing and growing without normal controls, causing an abnormal growth called a tumor.
Breast Cancer Introduction Cancer of the breast is the most common form of cancer that affects women but is no longer the leading cause of cancer deaths. About 1 out of 8 women are diagnosed with breast
Male breast cancer - Wikipedia, the free encyclopedia
pagina 1 van 5 Male breast cancer From Wikipedia, the free encyclopedia Male breast cancer is a relatively rare cancer in men that originates from the breast. As it presents a similar pathology as female
Tumour Markers. What are Tumour Markers? How Are Tumour Markers Used?
Dr. Anthony C.H. YING What are? Tumour markers are substances that can be found in the body when cancer is present. They are usually found in the blood or urine. They can be products of cancer cells or
BREAST CANCER PATHOLOGY
BREAST CANCER PATHOLOGY FACT SHEET Version 4, Aug 2013 This fact sheet was produced by Breast Cancer Network Australia with input from The Royal College of Pathologists of Australasia I m a nurse and know
SECOND PRIMARY BREAST CANCERS FOLLOWING HAEMATOLOGIC MALIGNANCIES A CASE SERIES STUDY FARAH TANVEER PGY 3 DR.MEIR WETZLER DR.
SECOND PRIMARY BREAST CANCERS FOLLOWING HAEMATOLOGIC MALIGNANCIES A CASE SERIES STUDY FARAH TANVEER PGY 3 DR.MEIR WETZLER DR. TRACEY O CONNOR RESEARCH QUESTON Patients with previously diagnosed hematologic
Report series: General cancer information
Fighting cancer with information Report series: General cancer information Eastern Cancer Registration and Information Centre ECRIC report series: General cancer information Cancer is a general term for
HAVE YOU BEEN NEWLY DIAGNOSED with DCIS?
HAVE YOU BEEN NEWLY DIAGNOSED with DCIS? Jen D. Mother and volunteer. Diagnosed with DCIS breast cancer in 2012. An educational guide prepared by Genomic Health This guide is designed to educate women
Prognostic and Predictive Factors in Oncology. Mustafa Benekli, M.D.
Prognostic and Predictive Factors in Oncology Mustafa Benekli, M.D. NCI Definitions ESMO Course -Essentials of Medical Oncology -Istanbul 2 Prognostic factor: NCI Definition A situation or condition, or
Immunohistochemical differentiation of metastatic tumours
Immunohistochemical differentiation of metastatic tumours Dr Abi Wheal ST1. TERA 3/2/14 Key points from a review article written by Daisuke Nonaka Intro Metastatic disease is the initial presentation in
Introduction Breast cancer is cancer that starts in the cells of the breast. Breast cancer happens mainly in women. But men can get it too.
Male Breast Cancer Introduction Breast cancer is cancer that starts in the cells of the breast. Breast cancer happens mainly in women. But men can get it too. Many people do not know that men can get breast
Seattle. Case Presentations. Case 1. 76 year old female with a history of breast cancer 12 years ago. Now presents with a pleural effusion.
Seattle Montreal IAP September 2006 Case Presentations Allen M. Gown, M.D. Medical Director and Chief Pathologist PhenoPath Laboratories Clinical Professor of Pathology University of British Columbia Case
Patient Guide to Breast Cancer Surgery and Treatment
Patient Guide to Breast Cancer Surgery and Treatment Coree H. Flight attendant and mother of 3. Diagnosed with invasive breast cancer in 2009. An educational guide prepared by Genomic Health This Is Your
About breast cancer i
About breast cancer i About us Breast Cancer Network Australia (BCNA) is the peak organisation for all people affected by breast cancer in Australia. We provide a range of free resources, including the
Breast Cancer Treatment Guidelines
Breast Cancer Treatment Guidelines DCIS Stage 0 TisN0M0 Tamoxifen for 5 years for patients with ER positive tumors treated with: -Breast conservative therapy (lumpectomy) and radiation therapy -Excision
Guide to Understanding Breast Cancer
An estimated 220,000 women in the United States are diagnosed with breast cancer each year, and one in eight will be diagnosed during their lifetime. While breast cancer is a serious disease, most patients
Breast Cancer. Treatment Guidelines for Patients
Breast Cancer Treatment Guidelines for Patients Version IX/ July 2007 Current ACS-NCCN Treatment Guidelines for Patients Advanced Cancer and Palliative Care Treatment Guidelines for Patients (English and
Breast Cancer in Men. What is cancer?
What is cancer? Breast Cancer in Men The body is made up of trillions of living cells. Normal body cells grow, divide into new cells, and die in an orderly way. During the early years of a person's life,
www.downstatesurgery.org
Male Breast Cancer Rabih Nemr MD Kings County Hospital August 2008 ACGME Core Competencies 1 Patient t Care Medical Knowledge 2 g 3 4 Practice Based Learning/Improvement Interpersonal Communication Skills
Chapter 2 Staging of Breast Cancer
Chapter 2 Staging of Breast Cancer Zeynep Ozsaran and Senem Demirci Alanyalı 2.1 Introduction Five decades ago, Denoix et al. proposed classification system (tumor node metastasis [TNM]) based on the dissemination
Florida Breast Health Specialists Breast Cancer Information and Facts
Definition Breast cancer is a cancer that starts in the tissues of the breast. There are two main types of breast cancer: Ductal carcinoma starts in the tubes (ducts) that move milk from the breast to
The Endocrine System
Essentials of Human Anatomy & Physiology Elaine N. Marieb Seventh Edition Chapter 9 The Endocrine System Slides 9.1 9.48 Lecture Slides in PowerPoint by Jerry L. Cook The Endocrine System Second messenger
PREPARED FOR: U.S. Army Medical Research and Materiel CommandFort Detrick, Maryland 21702 5012
AD Award Number: W81XWH 07 1 0542 TITLE: Is Nuclear Structure Altered in Breast Cancer Cells? PRINCIPAL INVESTIGATOR: Han Htun, Ph.D. CONTRACTING ORGANIZATION: University of California Los Angeles, CA
Académie internationale de Pathologie - Division arabe XX ème congrès 24-26 novembre 2008 Alger. Immunohistochemistry in malignant mesotheliomas
Académie internationale de Pathologie - Division arabe XX ème congrès 24-26 novembre 2008 Alger Immunohistochemistry in malignant mesotheliomas Françoise Thivolet-Béjui Groupement Hospitalier Est Lyon-Bron
Adjuvant Therapy for Breast Cancer: Questions and Answers
CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Adjuvant Therapy for Breast
Breast Cancer and Treatment
PATIENT EDUCATION patienteducation.osumc.edu Breast cancer affects nearly 200,000 women each year in the United States. The risk of developing breast cancer over a lifetime is 1 in 8, or 12%. Breast cancer
Participate in Cancer Screening
Key #3 Participate in Cancer Screening What is Cancer? The National Cancer Institute defines cancer as A term for diseases in which abnormal cells divide without control and can invade nearby tissues.
Male. Female. Death rates from lung cancer in USA
Male Female Death rates from lung cancer in USA Smoking represents an interesting combination of an entrenched industry and a clearly drug-induced cancer Tobacco Use in the US, 1900-2000 5000 100 Per Capita
General Rules SEER Summary Stage 2000. Objectives. What is Staging? 5/8/2014
General Rules SEER Summary Stage 2000 Linda Mulvihill Public Health Advisor NCRA Annual Meeting May 2014 National Center for Chronic Disease Prevention and Health Promotion Division of Cancer Prevention
Frequently Asked Questions About Ovarian Cancer
Media Contact: Gerri Gomez Howard Cell: 303-748-3933 gerri@gomezhowardgroup.com Frequently Asked Questions About Ovarian Cancer What is ovarian cancer? Ovarian cancer is a cancer that forms in tissues
The best treatment Your guide to breast cancer treatment in England and Wales
The best treatment Your guide to breast cancer treatment in England and Wales If you are looking for information on the treatment of secondary breast cancer (also known as advanced or metastatic breast
Breast Cancer Understanding your diagnosis
Breast Cancer Understanding your diagnosis Let s Make Cancer History 1 888 939-3333 cancer.ca Breast Cancer Understanding your diagnosis When you first hear that you have cancer, you may feel alone and
R-16: Chronic nonspecific cervisit
R-16: Chronic nonspecific cervisit Ectoservikal squamous epithelium Endoservical columnar epithelium Dilated cystic endoservical glands lymphoplasmocytes R18:Squamous cell carcinoma insitu Neoplastic epithelium
Breast Cancer. Treatment Guidelines for Patients
Breast Cancer Treatment Guidelines for Patients Version VIII/ September 2006 Current ACS/NCCN Treatment Guidelines for Patients Advanced Cancer and Palliative Care Treatment Guidelines for Patients (English
Early-stage Breast Cancer Treatment: A Patient and Doctor Dialogue
page 1 Early-stage Breast Cancer Treatment: A Patient and Doctor Dialogue Q: What is breast cancer, and what type do I have? A: Cancer is a disease in which cells become abnormal and form more cells in
Effects of Herceptin on circulating tumor cells in HER2 positive early breast cancer
Effects of Herceptin on circulating tumor cells in HER2 positive early breast cancer J.-L. Zhang, Q. Yao, J.-H. Chen,Y. Wang, H. Wang, Q. Fan, R. Ling, J. Yi and L. Wang Xijing Hospital Vascular Endocrine
Breast Health Starts Here
Breast Health Starts Here k Breast Health Knowledge and self-awareness are powerful tools. Understanding and utilizing these tools starts with Lake Charles Memorial s Breast Health Program. Developing
Identification of CD4+ T cell epitopes specific for the breast cancer associated antigen NY-BR-1
9/8/2015 Identification of CD4+ T cell epitopes specific for the breast cancer associated antigen NY-BR-1 Stefan Eichmüller, PhD GMP & T Cell Therapy Unit, German Cancer Research Center, Heidelberg, Germany
What is New in Oncology. Michael J Messino, MD Cancer Care of WNC An affiliate of Mission hospitals
What is New in Oncology Michael J Messino, MD Cancer Care of WNC An affiliate of Mission hospitals Personalized Medicine Personalized Genomics Genomic Medicine Precision Medicine Definition Application
Effusions: Mesothelioma and Metastatic Cancers
Effusions: Mesothelioma and Metastatic Cancers Malignant Mesothelioma Incidence: 2,500 cases/year ~60-80% pts with pleural MM relationship with asbestos exposure Other risk factors: radiation, other carcinogens,
A Guide to Breast Imaging: The Latest Technology for Screening and Detecting Breast Cancer
A Guide to Breast Imaging: The Latest Technology for Screening and Detecting Breast Cancer Sally Herschorn, MD Associate Professor of Radiology University of Vermont College of Medicine Medical Director
Human Anatomy & Physiology I with Dr. Hubley. Practice Exam 1
Human Anatomy & Physiology I with Dr. Hubley Practice Exam 1 1. Which definition is the best definition of the term gross anatomy? a. The study of cells. b. The study of tissues. c. The study of structures
Monoclonal Antibodies in Cancer. Ralph Schwall, PhD Associate Director, Translational Oncology Genentech, Inc.
Monoclonal Antibodies in Cancer Ralph Schwall, PhD Associate Director, Translational Oncology Genentech, Inc. Disclaimer I had nothing to do with Herceptin Using lessons learned in new antibody projects
IMMUNOHISTOCHEMICAL EXPRESSION IN MALE BREAST CANCER: TWO CASE REPORTS
Immunohistochemical expression in male breast cancer IMMUNOHISTOCHEMICAL EXPRESSION IN MALE BREAST CANCER: TWO CASE REPORTS Shih-Wen Hu, 1,2 Je-Hen Chuang, 3 and Kun-Bow Tsai 1,2 1 Department of Pathology
Developed by the Cancer Detection Section California Department of Public Health January, 2010 Cancer Detection Programs: Every Woman Counts
a Woman s Guide to Breast Cancer Treatment Developed by the Cancer Detection Section California Department of Public Health January, 2010 Cancer Detection Programs: Every Woman Counts table of contents
Mutations: 2 general ways to alter DNA. Mutations. What is a mutation? Mutations are rare. Changes in a single DNA base. Change a single DNA base
Mutations Mutations: 2 general ways to alter DNA Change a single DNA base Or entire sections of DNA can move from one place to another What is a mutation? Any change in the nucleotide sequence of DNA Here
MALE BREAST CANCER - CASE REPORT AND BRIEF REVIEW
Middle East Journal of Family Medicine, 2004; Vol. 6 (6) MALE BREAST CANCER - CASE REPORT AND BRIEF REVIEW Elias A Sarru', MD, MS, AAFP, ABFP Family Physician, Al Hasa Primary Care Services Division Faysal
What is DCIS? Contents. The breasts
This information is an extract from the booklet Understanding ductal carinoma in situ (DCIS). You may find the full booklet helpful. We can send you a free copy see page 6. Contents The breasts What is
National Cancer Institute
National Cancer Institute What You Need To Know About Breast Cancer U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Cancer Institute Services This is only one of many
Endocrine Glands and the General Principles of Hormone Action
Endocrine Glands and the General Principles of Hormone Action Cai Li, Ph.D. Assistant professor Touchstone Center for Diabetes Research Departments of Physiology and Internal Medicine The University of
MUTATION, DNA REPAIR AND CANCER
MUTATION, DNA REPAIR AND CANCER 1 Mutation A heritable change in the genetic material Essential to the continuity of life Source of variation for natural selection New mutations are more likely to be harmful
Breast Cancer Toolkit. Marion DePuit, MSN, Faith Community Nurse. Leslie Brown, BA, Community Advocate 9/2014. Understanding Breast Cancer
GENERAL: Breast Cancer Toolkit Marion DePuit, MSN, Faith Community Nurse Leslie Brown, BA, Community Advocate 9/2014 Understanding Breast Cancer (Adapted from the American Cancer Society and Breast Cancer.org)
OBJECTIVES By the end of this segment, the community participant will be able to:
Cancer 101: Cancer Diagnosis and Staging Linda U. Krebs, RN, PhD, AOCN, FAAN OCEAN Native Navigators and the Cancer Continuum (NNACC) (NCMHD R24MD002811) Cancer 101: Diagnosis & Staging (Watanabe-Galloway
Gail Kwarciany MSN RN-BC OCN AOCNS. February 2013
Gail Kwarciany MSN RN-BC OCN AOCNS February 2013 1. List 3 risk factors for breast cancer development 2. State 3 common signs & symptoms of breast cancer 3. Describe the ACS and NCI breast cancer screening
Breast Cancer. What is breast cancer?
Breast Cancer What is breast cancer? Breast cancer starts when cells in the breast begin to grow out of control. These cells usually form a tumor that can often be seen on an x-ray or felt as a lump. The
CD22 Antigen Is Broadly Expressed on Lung Cancer Cells and Is a Target for Antibody-Based Therapy
CD22 Antigen Is Broadly Expressed on Lung Cancer Cells and Is a Target for Antibody-Based Therapy Joseph M. Tuscano, Jason Kato, David Pearson, Chengyi Xiong, Laura Newell, Yunpeng Ma, David R. Gandara,
190.25 - Alpha-fetoprotein
Other Names/Abbreviations AFP 190.25 - Alpha-fetoprotein Alpha-fetoprotein (AFP) is a polysaccharide found in some carcinomas. It is effective as a biochemical marker for monitoring the response of certain
NEOPLASIA (4) Tumor-Host Interactions and Systemic Effects of Neoplasms
NEOPLASIA (4) Tumor-Host Interactions and Systemic Effects of Neoplasms Rex Bentley, M.D. Department of Pathology M216A, Duke South Green Zone Rex.Bentley@duke.edu 684-6423 NEOPLASIA (IV) Goals and Objectives
http://www.springer.com/3-540-22006-2
http://www.springer.com/3-540-22006-2 1 Molecular Pathology Laboratory of the Future Christopher A. Moskaluk 1.1 The Past The integration of laboratory analysis with human medicine has traditionally been
Breast Cancer. What is breast cancer? The normal breast
Breast Cancer What is breast cancer? Cancer starts when cells begin to grow out of control. Cells in nearly any part of the body can become cancer, and can spread to other areas of the body. To learn more
Immunostain Update: Diagnosis of Metastatic Breast Carcinoma, Emphasizing the Distinction from Gynecologic Cancers
Immunostain Update: Diagnosis of Metastatic Breast Carcinoma, Emphasizing the Distinction from Gynecologic Cancers Yunn-Yi Chen, M.D., Ph.D. UCSF Pathology Department yunn-yi.chen@ucsf.edu June 3, 2010
Pathologic Assessment Of The Breast And Axilla After Preoperative Therapy
Pathologic Assessment Of The Breast And Axilla After Preoperative Therapy W. Fraser Symmans, M.D. Associate Professor of Pathology UT M.D. Anderson Cancer Center Pathologic Complete Response (pcr) Proof
Feeling Your Way To Healthy Breast. Lisa Barnes, BSN, RN Ruth Fay,B.A.,M.B.A.,RN Mary Grady, BSN, RN Margaret Richmond, MA, RN
Feeling Your Way To Healthy Breast Lisa Barnes, BSN, RN Ruth Fay,B.A.,M.B.A.,RN Mary Grady, BSN, RN Margaret Richmond, MA, RN WHAT ARE MY BREASTS MADE OF? A breast is made of three main parts: glands,
YOUR LUNG CANCER PATHOLOGY REPORT
UNDERSTANDING YOUR LUNG CANCER PATHOLOGY REPORT 1-800-298-2436 LungCancerAlliance.org A GUIDE FOR THE PATIENT 1 CONTENTS What is a Pathology Report?...3 The Basics...4 Sections of a Pathology Report...7
Types of Cancers [-oma growth ]!
![Types of Cancers [-oma growth ]!](/thumbs/27/10363750.jpg "Types of Cancers [-oma growth ]!")
Cancer: disease of transcription factors and replication 1 Uncontrolled cell growth and division -> immortalized cells -> tumor growth -> metastasis (cells float away from tumor and spread throughout the
FRIEND TO FRIEND CPT CODES 2015 2016. Diagnostic digital breast tomosynthesis, unilateral (list separately in addition to code for primary procedure)
FRIEND TO FRIEND CPT CODES 2015 2016 CPT CODE SERVICE DESCRIPTION FEE EFFECTIVE G0101 Screening pelvic examination $36.69 01 Jan 16 G0202 Mammography, screening, digital, bilateral (2 view film study of
Cytopathology Case Presentation #8
Cytopathology Case Presentation #8 Emily E. Volk, MD William Beaumont Hospital, Troy, MI Jonathan H. Hughes, MD Laboratory Medicine Consultants, Las Vegas, Nevada Clinical History 44 year old woman presents
A23: Oncologic Disease- Tumor Markers
A23: Oncologic Disease- Tumor Markers Diagnosis Tumor Markers and Genetic Markers Use for Specific Malignancy The following information is from multiple guideline sources as recommendations for use of
Wisconsin Cancer Data Bulletin Wisconsin Department of Health Services Division of Public Health Office of Health Informatics
Wisconsin Cancer Data Bulletin Wisconsin Department of Health Services Division of Public Health Office of Health Informatics In Situ Breast Cancer in Wisconsin INTRODUCTION This bulletin provides information
October is Breast Cancer Awareness Month!
October is Breast Cancer Awareness Month! A STUDY OF CHARACTERISTICS AND MANAGEMENT OF BREAST CANCER IN TAIWAN Eric Kam-Chuan Lau, OMS II a, Jim Yu, OMSII a, Christabel Moy, OMSII a, Jian Ming Chen, MD
Abstract Introduction. Aim of the study. Conclusion. Patients and methods. Keywords. Results. R. Abo El Hassan 1, M. Moneer 2
Original Study Outcome of HER2 positive luminal operable breast cancer in comparison with outcome of other operable luminal breast cancer patients: Long follow-up of single center randomized study R. Abo
regulation of ECF composition and volume regulation of metabolism thyroid hormones, epinephrine, growth hormone, insulin and glucagon
Hormonal Effects regulation of ECF composition and volume ADH, aldosterone, ANF regulation of metabolism thyroid hormones, epinephrine, growth hormone, insulin and glucagon regulation of muscle contraction
Prognostic and Predictive Factors in Breast Cancer Kyle T. Bradley, MD, MS CAP Cancer Committee
Prognostic and Predictive Factors in Breast Cancer Kyle T. Bradley, MD, MS CAP Cancer Committee Breast cancer is the most common malignant tumor in American women and is second only to lung cancer as a
Access to hormone receptor testing and other basic diagnostic pathology services in Colombia
Access to hormone receptor testing and other basic diagnostic pathology services in Colombia Dr Fernando Perry Clínica de seno y tejidos blandos Instituto Nacional de Cancerología de Colombia Breast cancer
Outline. Workup for metastatic breast cancer. Metastatic breast cancer
Metastatic breast cancer Immunostain Update: Diagnosis of metastatic breast carcinoma, emphasizing distinction from GYN primary 1/3 of breast cancer patients will show metastasis 1 st presentation or 20-30
Mammography AND CLINICAL BREAST EXAMS. joytolife.org WHAT YOU SHOULD KNOW ABOUT BREAST CANCER HOW TO DO A BREAST SELF-EXAM EARLY DETECTION SAVES LIVES
Mammography AND CLINICAL BREAST EXAMS WHAT YOU SHOULD KNOW ABOUT BREAST CANCER HOW TO DO A BREAST SELF-EXAM joytolife.org EARLY DETECTION SAVES LIVES As a woman, you face many special concerns that call
Recombinant DNA and Biotechnology
Recombinant DNA and Biotechnology Chapter 18 Lecture Objectives What Is Recombinant DNA? How Are New Genes Inserted into Cells? What Sources of DNA Are Used in Cloning? What Other Tools Are Used to Study
Corporate Medical Policy Urinary Tumor Markers for Bladder Cancer
Corporate Medical Policy Urinary Tumor Markers for Bladder Cancer File Name: Origination: Last CAP Review: Next CAP Review: Last Review: urinary_tumor_markers_for_bladder_cancer 5/2011 11/2015 11/2016
NET della mammella: realtà o fantasia
NET della mammella: realtà o fantasia Roberto BALDELLI M.D., Ph.D. Regina Elena, Italian National Cancer Institute, Rome Unit of Endocrinology baldelli@ifo.it Tumors arising from enterochromaffin cells
Lung cancer and normal cell lines
The Essentials of Life Science Research Globally Delivered Lung and normal cell lines ATCC No. Name Tissue Cell Type Disease Oganism Age Ethnicity Genes Expressed CRL-5844 NCI-H838 [H838] 3B, adenocarcinoma;
The best treatment Your guide to breast cancer treatment in Scotland
The best treatment Your guide to breast cancer treatment in Scotland If you are looking for information on secondary breast cancer treatment, please see Breast Cancer Now s website: breastcancernow.org/
National Cancer Institute. What You Need TM. To Know About. Breast Cancer. U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health
National Cancer Institute What You Need TM To Know About Breast Cancer U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Cancer Institute Services This is only one of
Breast Anatomy and Physiology Unit 1. Bonnie A. Barnes, BA, R.T.,(R)(M)(CT)(f) Xuan Ho, Ph.D., R.T.(R)
Breast Anatomy and Physiology Unit 1 Bonnie A. Barnes, BA, R.T.,(R)(M)(CT)(f) Xuan Ho, Ph.D., R.T.(R) Key to Quality Mammograms Knowing the anatomy How to position Applying adequate compression Breast
Short guide on academic writing style.
Short guide on academic writing style. Audience. Not a teacher! Your reader has a background which is similar to yours before you started to work on this project. Title. Good title is usually short, straightforward
Personalized Medicine for Triple Negative Breast Cancer - New Dimensions in Therapeutic Individualization
Personalized Medicine for Triple Negative Breast Cancer - New Dimensions in Therapeutic Individualization Bryan P. Schneider & Milan Radovich Medicine & Medical Molecular Genetics Indiana University School
Breast Cancer. Understanding your diagnosis
Breast Cancer Understanding your diagnosis Breast Cancer Understanding your diagnosis When you first hear that you have cancer, you may feel alone and afraid. You may be overwhelmed by the large amount
Ductal carcinoma in situ (DCIS)
DIAGNOSIS: DCIS Ductal carcinoma in situ (DCIS) This factsheet gives information on an early form of breast cancer called ductal carcinoma in situ (DCIS). It explains what it is, how your breast is made
Progress and Prospects in Ovarian Cancer Screening and Prevention
Progress and Prospects in Ovarian Cancer Screening and Prevention Rebecca Stone, MD MS Assistant Professor Kelly Gynecologic Oncology Service The Johns Hopkins Hospital 1 No Disclosures 4/12/2016 2 Ovarian
Breast cancer: Diagnosis and complex treatment. Ibolya Czegle MD PhD Semmelweis University 3rd Department of Internal Medicine
Breast cancer: Diagnosis and complex treatment Ibolya Czegle MD PhD Semmelweis University 3rd Department of Internal Medicine Epidemiology Worldwide, breast cancer is the most frequently diagnosed life-threatening
DETERMINATION OF HER2 STATUS IN BREAST CANCER PATIENTS BY TWO METHODS: REAL-TIME QUANTITATIVE PCR (QPCR) AND IMMUNOENZIMATIC ASSAY (EIA)
DETERMINATION OF HER2 STATUS IN BREAST CANCER PATIENTS BY TWO METHODS: REAL-TIME QUANTITATIVE PCR (QPCR) AND IMMUNOENZIMATIC ASSAY (EIA) Maria Savino, Paola Parrella, Massimiliano Copetti, Raffaela Barbano,